Qiagen NV | QIA - Operating Profit


Qiagen NV reported $116.63M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alaunos Therapeutics USD -1.01M 175K Mar/2026
argenx SE USD 493M 99M Jun/2026
Avita Medical AUD -10.41M 742K Dec/2025
Dianthus Therapeutics USD -46.53M 23.01M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
IQVIA Holdings USD 565M 2.11B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Organon & Co USD 266M 49M Mar/2026
Qiagen NV USD 116.63M 5.25M Mar/2026
Revvity USD 82.77M 63.06M Mar/2026
Tectonic Therapeutic USD -27.3M 5.78M Mar/2026
Viatris USD -20.2M 137.3M Mar/2026
Xeris Pharmaceuticals USD 7.92M 8.86M Mar/2026